Myovant Sciences Price to Book Ratio 2017-2022 | MYOV
Historical price to book ratio values for Myovant Sciences (MYOV) over the last 10 years. The current price to book ratio for Myovant Sciences as of January 25, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Myovant Sciences Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-01-26 |
26.90 |
|
0.00 |
| 2022-09-30 |
17.96 |
$-5.32 |
-3.38 |
| 2022-06-30 |
12.43 |
$-5.05 |
-2.46 |
| 2022-03-31 |
13.32 |
$-4.99 |
-2.67 |
| 2021-12-31 |
15.57 |
$-4.62 |
-3.37 |
| 2021-09-30 |
22.44 |
$-4.11 |
-5.45 |
| 2021-06-30 |
22.77 |
$-4.35 |
-5.24 |
| 2021-03-31 |
20.58 |
$-3.89 |
-5.29 |
| 2020-12-31 |
27.62 |
$-2.98 |
-9.27 |
| 2020-09-30 |
14.05 |
$-2.21 |
-6.37 |
| 2020-06-30 |
20.62 |
$-1.49 |
-13.81 |
| 2020-03-31 |
7.55 |
$-1.21 |
-6.26 |
| 2019-12-31 |
15.52 |
$-0.54 |
-28.50 |
| 2019-09-30 |
5.20 |
$0.19 |
27.01 |
| 2019-06-30 |
9.05 |
$0.89 |
10.19 |
| 2019-03-31 |
23.87 |
$0.06 |
397.17 |
| 2018-12-31 |
16.41 |
$0.66 |
24.86 |
| 2018-09-30 |
26.55 |
$1.23 |
21.67 |
| 2018-06-30 |
22.87 |
$0.93 |
24.67 |
| 2018-03-31 |
21.27 |
$0.62 |
34.39 |
| 2017-12-31 |
12.64 |
$1.35 |
9.38 |
| 2017-09-30 |
15.47 |
$1.95 |
7.93 |
| 2017-06-30 |
11.70 |
$2.40 |
4.88 |
| 2017-03-31 |
11.74 |
$2.77 |
4.24 |
| 2016-12-31 |
12.44 |
$3.09 |
4.03 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.604B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
